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Background: Declining cognitive function is relatively common and increasingly prevalent. Studies have shown
that different nutrients (e.g., Ginkgo biloba and vitamin E) appear to be effective at improving memory and
concentration, while less is known about their effect on immunity.
Methods: This study investigated the effect of Ginkgo Synergy® plus Choline (n = 33) and OPC Synergy® plus
Catalyn® (n = 31) versus placebo (n = 33) in a 6-month, randomized, double-blind trial on cognitive and immune
functioning among English-speaking, non-smoking, healthy older adults. The Stroop Color and Word Test, Trail
Making Test A and B, Controlled Oral Word Association, Hopkins Verbal Learning, Mini-Mental State Exam, and Digit
Symbol were administered at baseline and 3 and 6 months follow-up to assess cognitive functioning. Cytokines
and growth factors were measured at baseline and 6 months to assess inflammation and immune functioning. Data
were analyzed with linear mixed modeling.
Results: No serious adverse events were noted in this study. According to time on the Trail Making Test-B, the
Ginkgo Synergy® plus Choline arm showed improvement from baseline to 3 months follow-up (mean difference = 24.2;
SE = 6.4; 95% CI: 8.6, 39.7; p = 0.01). On the Controlled Oral Word Association Trial-S, the scores significantly increased
for the Ginkgo Synergy® plus Choline arm from baseline to 6 months follow-up (mean difference = 2.1; SE = 0.8;
95% CI: 0.2, 3.9; p < 0.05) and for the OPC Synergy® plus Catalyn® arm from baseline to 3 months follow-up
(mean difference = 2.1; SE = 0.8; 95% CI: 0.2, 4.0; p < 0.05). Epidermal growth factor significantly decreased from
baseline to 6 months follow-up for the Ginkgo Synergy® plus Choline arm (mean difference = 120.7; SE = 28.4; 95%
CI: 62.6, 178.8; p < 0.001).
Conclusions: Our study showed isolated and modest effects of a Ginkgo biloba plus choline-based formula on
cognitive and immune functioning among healthy older adults with no history of significant cognitive deficits. Our
trial was registered with clinicaltrials.gov (ID: NCT01672359). This study was supported by a grant from Standard
Process, Inc.
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Approximately 5 million Americans suffer from some
form of dementia, the leading cause of institutionalization
among the elderly [1]. Alzheimer’s disease (AD), the most
common form of dementia, accounts for over two-thirds
of the cases. The number of people over the age of 65 will
triple and those over the age of 85 will quadruple in the
next 50 years, and 14 million Americans will be diagnosed
with AD by the middle of the 21st century [2].
Conventional Western medicine cannot prevent cognitive
decline, leaving many consumers turning to alternative
treatments, such as nutritional therapies [2]. Total sales of
dietary supplements, including those touted to enhance
cognition, were estimated at over $30 billion in 2010 [3].
Among males and females 60 and older, the rate of dietary
supplement use was higher, compared to males and
females between 20 and 59 (42% and 54% vs. 35% and
47%, respectively) [4]. Many herbs are also consumed with
inconsistencies in usage attributed to variation in the
definition of herbs and the length of use [5].
Several clinical trials have utilized Ginkgo biloba to
assess the effect of dietary supplements on cognition
[6-8]. A meta-analysis among studies of AD patients
with Ginkgo biloba revealed a small effect size of 0.40
(p < 0.0001) on cognitive function [9]. Other nutrients
may hold promise as well, e.g., pre-clinical data have
showed that grape seed may be effective for preventing
cognitive decline, while decreasing β-amyloid proteins
in the brain [10]. Additionally, aging is accompanied by
systemic inflammation, and cytokines have been associ-
ated with cognitive decline in older individuals [11,12].
However, the relationship between cytokine-mediated
physiological processes with aging and cognitive decline
remains poorly understood.
Our study extends the evaluative process of nutritional
therapies through a randomized, double-blind, placebo-
controlled clinical trial assessing a regimen of dietary
supplements’ efficacy. We hypothesized that two dietary
supplement formulae consisting of Ginkgo Synergy® plus
Choline or OPC Synergy® plus Catalyn® would result in
improved cognitive and immune functioning compared
to placebo in a sample of healthy older individuals.
Methods
Study participants
The study was conducted with the approval of the University
of Miami Institutional Review Board for human subjects
research. Each subject signed informed consent and
HIPAA forms prior to study entry. Potential participants
(n = 144) were identified through referrals from offices at
the University of Miami Miller School of Medicine and
community centers in Miami-Dade, Broward, and Palm
Beach counties during May 2010 to December 2011. Out
of 121 eligible participants, 97 were enrolled (GinkgoSynergy® plus Choline, n = 33; OPC Synergy® plus Catalyn®,
n = 31; and placebo, n = 33). Please see Figure 1 for the
CONSORT flowchart.
Study design
Participants were randomized into a three-group, parallel,
placebo-controlled clinical trial to assess the efficacy of two
dietary supplement formulae on cognitive and immune
functioning in healthy older adults.
Inclusion and exclusion criteria
Inclusion criteria were: (a) 60+ years of age; (b) English
speaking; (c) not living in a nursing facility; (d) no use of
dietary supplements for cognitive functioning two weeks
before enrolling and during the intervention period; and
(e) a Mini-Mental State Exam (MMSE) score ≥23. Exclu-
sion criteria were: (a) AD or related disorders; (b) schizo-
phrenia, psychotic disorders, bipolar, major depression with
psychotic features, or delirium; (c) bleeding disorders; (d)
aphasia or sensory, motor, or visual disturbances that would
have interfered with testing; (e) cancer, cardiovascular,
pulmonary, renal, thyroid, hepatic, gastrointestinal diseases,
or insulin-dependent diabetes; (f) current cigarette smoking
or alcohol or substance abuse/dependence; (g) 3+ major
medical or psychiatric hospitalizations in the past year; (h)
a T score >70 on the Global Severity Index of the Brief
Symptoms Inventory (BSI); (i) a score ≥29 on the Beck
Depression Inventory-II (BDI); (j) prescription or OTC
sympathomimetic amines and antihistamines within 2 days
of an assessment visit; (k) cognition-enhancing drugs; or
(l) Coumadin, tricyclic antidepressants, antipsychotics, or
anticonvulsants.
Screening
Eligible participants completed the Short Portable Mental
Status Questionnaire (SPMSQ) and the Wechsler Memory
Scale III Story A (WMS-III-A). Subjects were allowed only
two errors on the SPMSQ. If they scored <6 points on
story A for the WMS-III-A, they were given a second
opportunity and had to score a 4+ on story B. If all pre-
screening criteria were achieved, subjects were scheduled
for the additional screening (MMSE, BSI, and BDI) and
the baseline assessment. Mental status was assessed with
the MMSE, providing a rapid screen of orientation, regis-
tration, attention and calculation, recall, and language
domains. As psychological distress and depression may
impair cognitive function, and thus lead to poor perform-
ance on outcome measures, participants were also evalu-
ated using the BSI and BDI.
Intervention and randomization
After screening and baseline, participants were randomly
assigned to one of three conditions: (a) Ginkgo Synergy®
(2 capsules/day providing 120 mg/day Ginkgo biloba leaf,
CONSORT 2010 Flow Diagram
Assessed for eligibility (n=144)
Excluded (n=47)
Not meeting inclusion criteria (n=23)
Declined to participate (n=24)
Analyzed (n=33)
Excluded from analysis (n=0)
Lost to follow-up (lost contact) (n=3)
Discontinued intervention (adverse event, 
voluntary withdrawal) (n=7)
Allocated to Ginkgo Synergy® plus 
Choline (n=33)
Received allocated intervention (n=33)
Lost to follow-up (lost contact) (n=2)
Discontinued intervention (adverse 
event, voluntary withdrawal) (n=5)
Analyzed (n=33)






Lost to follow-up (lost contact) (n=4)
Discontinued intervention (adverse event, 
voluntary withdrawal) (n=4)
Analyzed (n=33)
Excluded from analysis (n=0)
Allocated to OPC Synergy® plus 
Catalyn® (n=31)
Received allocated intervention (n=31)
Allocated to Placebo (n=33)
Received allocated intervention (n=33)
Figure 1 The CONSORT flowchart.
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http://www.biomedcentral.com/1472-6882/14/4380 mg/day Ginkgo biloba whole extract, 40 mg/day grape
seed extract, Gotu kola leaf (Centella asiatica), dried
buckwheat leaf juice, buckwheat seed, and soybean lecithin
powder) plus Choline (4 tablets/day providing 700 mg/day),
(b) OPC Synergy® (2 capsules/day providing 100 mg/day
grape seed extract, 50 mg/day green tea extract (60%
catechins), 50 mg/day bilberry fruit (25% anthocyanins),
dried buckwheat leaf and juice, green tea leaf powder,
and dried carrot root) plus Catalyn® (4 tablets/day providing
312 IU/day vitamin D, 1,600 IU/day vitamin A, 5.3 mg/day
vitamin C, 0.3 mg/day thiamine, 0.3 mg/day riboflavin,
1.3 mg/day vitamin B6, defatted wheat germ, carrot (root),
calcium lactate, nutritional yeast, bovine adrenal, bovine
liver, magnesium citrate, bovine spleen, ovine spleen, bovine
kidney, dried pea (vine) juice, dried alfalfa (whole plant)
juice, mushroom, oat flour, soybean lecithin, and rice bran),
or (c) placebo (cellulose, lactose, and beet powder) provided
by the manufacturer (Standard Process, Palmyra, WI).
The table of random permutations was created by one
of the authors (JEL). It was created in blocks of 10
subjects at a time, and study coordinators assigned par-
ticipants to an intervention arm in sequential fashion.
All subjects and investigators were blind to treatment
condition and remained blinded until after dataanalysis; only a staff member at Standard Process knew
the assignment.
Outcomes and assessments
All participants completed a basic sociodemographics
and medical history questionnaire and reported their list
of medications at baseline.
Cognitive measures
The neuropsychological assessment targeted executive
functioning, memory, and psychomotor speed and was
administered at baseline and 3 and 6 months follow-up.
Measures included the MMSE, the Stroop Color and Word
Test (SCWT), the Trail Making Test Parts A and B
(TMT-A, TMT-B), the Controlled Oral Word Association
test (COWA), the Digit Symbol subtest of the Wechsler
Adult Intelligence Scale, Third Edition (WAIS-III), and
the Hopkins Verbal Learning Test-Revised (HVLT-R).
The SCWT assesses response inhibition [13], the effects
of perceptual interference [14], concentration, and speed of
processing abilities, involving three distinct tasks. TMT-A
and TMT-B assess a person’s abilities to sequence and
shift perceptual sets, concentration and vigilance, and
visuomotor scanning and tracking speed [15], which reflect
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exceptional measures of general brain functioning [16]. The
COWA assesses verbal fluency and is sensitive to cerebral
dysfunction [17]. The WAIS-III Digit Symbol subtest
measures perceptual speed, during which the subject must
quickly copy symbols that are linked with numbers [18].
The HVLT-R assesses verbal and visuospatial recall and
recognition memory, containing two equivalent forms
to allow repeat testing without correction for practice
effects [19].
The administration of the battery required 60-90 minutes.
Participants were provided at least one break during the
testing session and were closely monitored for fatigue or
emotional distress. No participants suffered from excessive
fatigue to the point of needing to complete the assessment
on a later date.
Immune function markers
Venous blood was obtained at baseline and 6 months.
Blood samples were collected in EDTA tubes and frozen
within 2 hours of collection. Samples were sent to a
contract lab (Radix Biosolutions, Georgetown, TX) for
analysis. A commercially-available magnetic bead-based
Milliplex® MAG kit (Millipore Corporation MA) was used
to analyze all samples for: interleukin (IL)-2, IL-4, IL-6,
IL-8, IL-10, IL-1α, IL-1β, interferon (IFN)-γ, tumor ne-
crosis factor (TNF)-α, monocyte chemotactic protein
(MCP)-1, vascular endothelial growth factor (VEGF),
and epidermal growth factor (EGF). The kit included
two quality control samples, expected concentrations for
each sample, and all necessary reagents. The standard
curve and quality controls were prepared fresh each day.
Both quality control samples were run in duplicate before
and after each set of samples on each microtiter plate to
produce 2 concentration values per quality control sample
in each assay. Assays were set up sequentially, so all sam-
ples could be analyzed on the same day, utilizing five sep-
arate assay kits. Each sample was run neat in duplicate
wells and incubated at 4°C overnight. Sample reruns were
completed with the original samples and involved an add-
itional freeze/thaw cycle. The concentration of each cyto-
kine or growth factor in each plasma specimen was
calculated from the standard curve and reported in pg/ml.
Intervention protocol
Supplements were given to each participant at the baseline
and 3-month follow-up assessments to promote greater
compliance. Subjects were not advised to modify eating or
physical activity habits or prescription medication use. In
addition, they were instructed not to consume other dietary
supplements containing Ginkgo biloba, vitamin B complex
nutrients, vitamin E, or any other cognitive-enhancing
nutritional supplement. Subjects listed all dietary sup-
plements taken on the health history form, and productswere reviewed to ensure none of these nutrients was
consumed during the course of the trial. Regardless of
study arm assignment, subjects consumed 3 tablets 2
times per day with breakfast and dinner, i.e., 6 tablets per
day total. Each subject was compensated $35 per assess-
ment at baseline and 3 and 6 months follow-up.
Statistical analysis
Data were analyzed using SPSS 19 (IBM Inc., Chicago, IL)
for Windows. Frequency and descriptive statistics were
calculated on all variables. Analysis of variance and chi
square were utilized to determine the presence of differ-
ences in background contextual variables by study arm
assignment. We utilized linear mixed modeling (LMM)
to assess the fixed effect of time by randomization on
changes in our outcome variables from baseline to
6 months follow-up. If the type III test of the fixed effect
of time by randomization was significant, then we used
pairwise comparisons to determine the unique differences
in effects over time by study arm between baseline and
follow-up at 3 and 6 months for the cognitive assessment
and between baseline and 6 months for the physiological
variables. LMM with heterogeneous compound symmetry
covariance allowed us to account for subject attrition,
inter-correlated responses between time points, and non-
constant variability. Based on the results that Mix and
Crews found in response to a 6-week placebo-controlled
trial of Ginkgo biloba on the SCWT color-naming task [7],
we estimated an effect size of 5.25 units on the task, which
gave us power of roughly 80% with 31 subjects in each
group. The criterion for statistical significance was α = 0.05.
Results
Safety and tolerability
Three subjects withdrew from the study: (a) one placebo
group subject reported insomnia and heightened energy
at night; (b) one OPC Synergy® plus Catalyn® group subject
was diagnosed with ulcerative colitis shortly after enrolling
in the study; and (c) one Ginkgo Synergy® plus Choline
group subject reported joint aches that were not alleviated
by titrating the dose by 1/3 and then increasing the dose by
1/3 every 3 days. No other adverse events were reported.
Sociodemographics, health risk, and medication use
Table 1 presents sociodemographics by study arm. Only
race/ethnicity showed a statistically significant difference,
as more Hispanics were assigned to the Ginkgo Synergy®
plus Choline study arm (Χ2(4) = 14.2, p < 0.01). Table 2
displays the prevalence of current prescription medica-
tions and OTC remedies. A higher percentage of subjects
in the OPC Synergy® plus Catalyn® study arm was taking
some type of medication for dyslipidemia or high chol-
esterol (Χ2(2) = 6.3, p = 0.04). No other proportion was
significantly different.
Table 1 Sociodemographic characteristics of the sample
Variable Category Total sample
(n = 97)
(OPC Synergy® +
Catalyn®) (n = 31)
(Ginkgo Synergy® +
Choline) (n = 33)
Placebo (n = 33) Statistic
Age - M = 68.8 (SD = 7.2;
R = 58, 93)
M = 68.5 (SD = 6.7;
R = 59, 83)
M = 67.6 (SD = 6.3;
R = 58, 82)
M = 70.3 (SD = 8.3;
R = 60, 93)
F(2,96) = 1.2,
p = 0.30
Gender Male 27 (27.8%) 7 (22.6%) 8 (24.2%) 12 (36.4%) Χ2(2) = 1.3,
p = 0.40
Female 70 (72.2%) 24 (77.4%) 25 (75.8%) 21 (63.6%)
Race/ethnicity White, non-Hispanic 80 (82.5%) 27 (87.1%) 21 (63.6%) 32 (97.0%) Χ2(4) = 14.2,
p < 0.01
Black, non-Hispanic 2 (2.1%) 1 (3.2%) 1 (3.0%) -
Hispanic 15 (15.5%) 3 (9.7%) 11 (33.3%) 1 (3.0%)
Education Up to high school 12 (12.4%) 5 (16.1%) 5 (15.2%) 2 (6.1%) Χ2(6) = 11.4,
p = 0.08
Some post high school training 34 (35.1%) 11 (35.5%) 12 (36.4%) 11 (33.3%)
College graduate 24 (24.7%) 7 (22.6%) 12 (36.4) 5 (15.2%)
Master’s degree or higher 27 (27.8%) 8 (25.8%) 4 (12.1%) 15 (45.5%)
Marital status Never married 8 (8.2%) - 2 (6.1%) 6 (18.2%) Χ2(6) = 9.7,
p = 0.14
married 49 (50.5%) 16 (51.6%) 15 (45.5%) 18 (54.5%)
widowed 19 (19.6%) 8 (25.8%) 7 (21.2%) 4 (12.1%)
Divorced/separated 21 (21.6%) 7 (22.6%) 9 (27.3%) 5 (15.2%)
Note: M =Mean; SD = Standard Deviation; R = Range.
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We found no significant fixed effects for time, rando-
mization, or time by randomization for the Word T, Color
T, Color-Word T, Predicted Color-Word, or Interference
T on the SCWT or for the MMSE.Table 2 Prevalence of prescription and over-the-counter med




Current prescription Anti-depressant Yes 11 (11.3%)
No 86 (88.7%)
Beta blocker Yes 7 (7.2%)
No 90 (92.8%)
Anti-hypertensive Yes 25 (25.8%)
No 72 (74.2%)
Anti-hypercholesterol Yes 11 (11.3%)
No 86 (88.7%)
Laxative Yes 7 (7.2%)
No 90 (92.8%)
Insomnia Yes 10 (10.3%)
No 87 (89.7%)
OTC in the prior week Aspirin Yes 33 (34%)
No 64 (66%)
Tylenol Yes 34 (35.1%)
No 63 (64.9%)
Antacid Yes 13 (13.4%)
No 84 (86.6%)
Vitamin/mineral Yes 67 (69.1%)
No 30 (30.9%)For time and errors on the TMT-A, the fixed effects for
time, randomization, and time by randomization were
non-significant. For time on the TMT-B (see Figure 2), the
fixed effect for time by randomization was significant
(F[4,113.8] = 2.76, p < 0.05). Time significantly decreasedication usage
PC Synergy® +
atalyn®) (n = 31)
(Ginkgo Synergy® +




6 (19.4%) 1 (3%) 4 (12.1%) Χ2(2) = 4.3, p = 0.12
25 (80.6%) 32 (97%) 29 (87.9%)
4 (12.9%) 3 (9.1%) - Χ2(2) = 4.2, p = 0.12
27 (87.1%) 30 (90.1%) 33 (100%)
9 (29%) 9 (27.3%) 7 (21.2%) Χ2(2) = 0.6, p = 0.75
22 (71%) 24 (72.2%) 26 (78.8%)
7 (22.6%) 1 (3%) 3 (9.1%) Χ2(2) = 6.3, p = 0.04
19 (77.4%) 32 (97%) 30 (90.1%)
2 (6.5%) 3 (9.1%) 2 (6.1%) Χ2(2) = 0.3, p = 0.88
29 (93.5%) 30 (90.1%) 31 (93.9%)
3 (9.7%) 4 (12.1%) 3 (9.1%) Χ2(2) = 0.2, p = 0.91
28 (90.3%) 29 (87.9%) 30 (90.1%)
10 (32.3%) 14 (42.4%) 9 (27.3%) Χ2(2) = 1.8, p = 0.42
21 (67.7%) 19 (57.6%) 24 (72.2%)
12 (38.7%) 13 (39.4%) 9 (27.3%) Χ2(2) = 1.3, p = 0.51
19 (61.3%) 20 (60.6%) 24 (72.2%)
6 (19.4%) 5 (15.2%) 2 (6.1%) Χ2(2) = 2.6, p = 0.28
25 (80.6%) 28 (84.8%) 31 (93.9%)
21 (67.7%) 25 (75.8%) 21 (63.6%) Χ2(2) = 1.2, p = 0.56
10 (32.3%) 8 (24.2%) 12 (36.4%)
Figure 2 Trail Making Test Part B at baseline, 3 months, and 6
months. Baseline = Black, 3 months follow-up = light gray, 6 months
follow-up = dark gray; †Significantly different from baseline within
the same group (p = 0.01).
Figure 3 Controlled Oral Word Association Trial 3-S test at
baseline, 3 months, and 6 months. Baseline = Black, 3 months
follow-up = light gray, 6 months follow-up = dark gray; †Significantly
different from baseline within the same group (p = 0.05); *Significantly
different from Ginkgo Synergy/Choline and placebo at the same time
point (p = 0.05).
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6.4; 95% CI: 8.6, 39.7; p = 0.01), but not at 6 months (mean
difference = 14.6; SE = 7.1; 95% CI: -2.7, 32.0; p = 0.12) for
the Ginkgo Synergy® plus Choline study arm.
The Digit Symbol test included number correct, num-
ber incorrect, total score, and total proportion. For the
number correct, the fixed effect for time was significant
(F[2,139.1] = 6.6, p < 0.01), but the effects for randomization
and time by randomization were non-significant. For the
number incorrect, the fixed effect for time was significant
(F[2,133.9] = 5.7, p < 0.01), but the effects for randomization
and time by randomization were non-significant. For
the total score, the fixed effect for time was significant
(F[2,137.3] = 4.2, p < 0.05), but the effects for randomization
and time by randomization were non-significant. For the
total proportion, the fixed effect for time was significant
(F[2,139.0] = 5.3, p < 0.01), but the effects for randomization
and time by randomization were non-significant.
The results for the HVLT-R included total recall T score,
delayed recall T score, retention T score, and recognition
discrimination index T score. For the total recall T score,
the fixed effect for time was significant (F[2,100.4] = 10.4,
p < 0.001), but the effects for randomization and time by
randomization were non-significant. For the delayed
recall T score, the fixed effect for time was significant
(F[2,128.8] = 6.2, p < 0.01), but the effects for randomization
and time by randomization were non-significant. For the
retention T score and the recognition discrimination index
T score, no significant fixed effects were found.
For the COWA test, the fixed effect for time was
significant (F[2,124.5] = 7.3, p < 0.01), but the effects
for randomization and time by randomization were
non-significant on Trial 1-F. For Trial 2-A, the fixed effect
for time was significant (F[2,125.9] = 6.4, p < 0.05), but theeffects for randomization and time by randomization
were non-significant. For Trial 3-S (see Figure 3), the
fixed effects for time (F[2,129.8] = 4.1, p < 0.05) and
randomization (F[2,96.1] = 3.1, p = 0.05) were significant,
and the time by randomization effect was marginally sig-
nificant (F[4,129.9] = 2.2, p = 0.07). Post-hoc comparisons
revealed that the score at 3 months follow-up of the OPC
Synergy® plus Catalyn® study arm was significantly higher
than the Ginkgo Synergy® plus Choline (mean differ-
ence = 3.9; SE = 1.4; 95% CI: 0.5, 7.3; p < 0.05) and pla-
cebo (mean difference = 3.6; SE = 1.4; 95% CI: 0.3, 7.0;
p < 0.05) study arms. The score for the OPC Synergy®
plus Catalyn® study arm significantly increased from
baseline to 3 months follow-up (mean difference = 2.1;
SE = 0.8; 95% CI: 0.2, 4.0; p < 0.05), but did not continue
increasing at 6 months (mean difference = 1.0; SE = 0.8;
95% CI: -0.8, 2.9; p = 0.47). For the Ginkgo Synergy® plus
Choline study arm, the score significantly increased from
baseline to 6 months follow-up (mean difference = 2.1;
SE = 0.8; 95% CI: 0.2, 3.9; p < 0.05). The placebo group
showed no significant changes from baseline to 6 months
follow-up. For Trials 1-3 Total, the fixed effect for time
(F[2,130.7] = 13.0, p < 0.001) was significant, but the effects
for randomization and time by randomization were non-
significant.
Immune functioning
IL-4 was completely undetectable by the assay, other than
for 2 values at baseline. For IL-2, IL-6, IL-8, IL-10, IL-1α,
IFN-γ, TNF-α, and MCP-1, the fixed effects for time,
randomization, and time by randomization were non-
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6.3, p < 0.05) was significant, but the effects for rando-
mization and time by randomization were non-significant.
For VEGF, the fixed effect for time (F[1,41.2] = 5.9, p < 0.05)
was significant, but the effects for randomization and time
by randomization were non-significant. For EGF, the
time by randomization effect was marginally significant
(F[2,28.7] = 2.8, p = 0.08). Post-hoc comparisons revealed
that EGF for the Ginkgo Synergy® plus Choline study arm
significantly decreased from baseline to 6 months follow-up
(mean difference = 120.7; SE = 28.4; 95% CI: 62.6, 178.8;
p < 0.001). EGF did not significantly change for the OPC
Synergy® plus Catalyn® and placebo arms (see Figure 4).
Discussion
In the current study, we demonstrated several significant
and isolated improvements with two dietary supplement
formulae of Ginkgo Synergy® plus Choline and OPC
Synergy® plus Catalyn. The Ginkgo Synergy® plus Choline
study arm showed improvements after 3 months on the
TMT-B time score (68%) and after 6 months on the COWA
Trial-S score (18%). Globally, the TMT is a valid and re-
liable assessment used to detect impairment in many cog-
nitive areas [20]. The TMT-B has been shown to be a
valid indicator of executive functioning [21] and is likely
to be more sensitive to assessing cognitive flexibility [20].
The OPC Synergy® plus Catalyn® study arm showed an
11% improvement in the COWATrial-S score at 3 months
follow-up. The COWA assesses the ability to make verbal
associations to certain letters (in this case, “S”) [22]. It has
been used as a key part of neuropsychological testing to
rule out common cognitive disorders, and it has been
associated with frontal lobe lesions [23] and AD [24].
Our findings are similar to other studies that showed
improvements with Ginkgo biloba-based formulae in
certain aspects of cognitive functioning in healthy adults
[7,8] and among participants with probable AD [25].Figure 4 Epidermal growth factor at baseline and 6 months.
Baseline = Black and 6 months follow-up = gray; †Significantly
different from baseline within the same group (p = 0.001).Mix and Crews investigated the 6-week effect of Ginkgo
biloba extract (180 mg/day of EGb 761) compared to
placebo on cognitive functioning in 48 healthy elderly
(55 years of age and above) participants [7]. The partici-
pants on Ginkgo biloba extract significantly improved on
the SCWT (i.e., a task assessing speed of processing abil-
ities) at follow-up compared to participants on placebo,
and non-significant trends were noted on three of the four
remaining cognitive tasks involving a timed, processing
component. Additionally, more participants in the Ginkgo
biloba group rated their ability to remember at follow-up as
“improved” compared to the placebo group. Napryeyenko
and colleagues analyzed the data of 395 participants
(≥50 years of age) with dementia (214 with probable
AD or possible AD with cerebrovascular disease and 181
with probable vascular dementia) to assess the effect of
22 weeks of a Ginkgo biloba extract (EGb 761® 240 mg/
day) versus placebo on the Short Syndrome Test (SKT), a
cross-culturally validated cognitive test battery, the Neuro-
psychiatric Inventory, the Verbal Fluency Test, the
Clock-Drawing Test, the Hamilton Rating Scale for
Depression, and the Gottfries-Bråne-Steen Scale [25].
Those with AD and vascular dementia taking the Ginkgo
biloba extract had higher SKT total scores by -3.0 ± 2.3
and -3.4 ± 2.3, respectively, compared to the participants on
placebo whose scores decreased by +1.2 ± 2.5 and +1.5 ±
2.2 points, respectively (p < 0.01 for each drug-placebo dif-
ference). Significant drug-placebo differences were noted
for all other outcome variables with no differences between
AD and vascular dementia subgroups. Adverse events were
higher for the placebo group. Conversely, another study
failed to show any improvements with Ginkgo biloba on
memory and related mental functions among older adults
[6]. Solomon et al. investigated the effect of 40 mg per day
of Ginkgo biloba compared to placebo on cognitive func-
tioning for 6 weeks among 230 community-dwelling
healthy participants 60 years of age and older. The results
of the study did not result in any improvements in learning,
memory, attention, or concentration between the two
groups at the follow-up assessment [6]. Inconsistencies
in the findings of our study versus others can be due to
dose, plant form, extract strength, and other associated
production and quality factors.
Our study may be one of the first of its kind to assess
a panel of cytokines and growth factors before and after
dietary supplementation in healthy older adults. To our
knowledge, cytokines have been assessed (e.g., IL-1β,
TNF-α, and IL-6) in AD patients and compared to controls
or other disease groups, such as vascular dementia or
cerebrovascular disease, but typically only in cross-sectional
or observational studies and not clinical trials [26,27]. We
noted a significant decrease (57%) in EGF over the course
of the intervention in the Ginkgo Synergy® plus Choline
study arm. EGF and its receptor have been classically linked
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to poor prognosis and decreased survival [28]. Additionally,
EGF was recently shown to be over-expressed in those with
mild cognitive impairment (MCI) or AD compared to
healthy controls [29]. Moreover, plasma EGF may be a
biomarker for progression to MCI in Parkinson’s patients,
as it was correlated with cognitive functioning at baseline
and showed predictive capacity over time [30]. Given that
neuroinflammation may play a causative role in the patho-
genesis of neurodegenerative diseases [31], and many stud-
ies have demonstrated mechanistic links among multiple
inflammatory pathways in AD [32], finding a way to reduce
EGF may help to counteract some of these mechanisms of
action. Furthermore, our findings may lend support for the
pursuit of anti-EGF therapy, not only for preventing cancer
or disrupting carcinogenesis, but for decreasing the nega-
tive impact on cognitive functioning.
Limitations
Several limitations should be noted in the current investi-
gation. We enrolled a predominantly white, non-Hispanic,
well-educated sample, so our results may not be genera-
lizable to other populations. In this study, we did not
assess dietary intake or physical activity level, so we are
unsure how these variables could have affected the results
of the study. Nonetheless, subjects were advised not to take
any additional dietary supplements, modify their eating
habits, or change their physical activity level during the
course of the intervention. Our findings may be restricted
by the length of the intervention, given that cognitive
changes may take longer than 6 months to occur. With the
elevated scores in cognitive functioning and a high rate
(70%) of existing vitamin/mineral supplement use in our
sample, we may also have enrolled “very healthy” individ-
uals who were less sensitive to changes in dietary supple-
mentation. The results of our cytokine and growth factor
assays could have been unduly influenced by our partici-
pants’ medications that were not initially excluded in our
enrollment procedures [33]. For our blood sampling pro-
cedures, we utilized all leukocyte cell populations, which
could have affected the results of our immune functioning
markers [33]. Nonetheless, the Ficoll-Hypaque gradient is
easily replicated clinically, does not alter the function of
isolated cells, and is routinely used in many settings. Using
this methodology, 60-70% of the cells are lymphocytes,
while the remaining cells are monocytes and macrophages.
The findings of our study are also potentially limited by a
small sample size in each study arm.
Conclusions
The formulae used in the current study were well-tolerated
among all subjects, as is typically reported in the literature.
Our results show that the Ginkgo Synergy® plus Choline
formula is associated with isolated improvements incognitive and immune functioning. Our findings in cogni-
tion are generally consistent with prior work by other inves-
tigators using Ginkgo biloba. The OPC Synergy® plus
Catalyn® formula (containing antioxidants and A, B, C,
and D vitamins) was less effective than Gingko biloba in
our study. Its benefit was associated with isolated and
short-term improvement in verbal fluency. In summary,
our study shows that a high-quality, concentrated
Gingko biloba plus choline formula is safe and may offer
modest cognitive and immunological benefits, among
healthy older adults with no cognitive impairments.
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